Bronchiectasis: morbidity and mortality in Brazil and its impact on hospitalization rates
DOI:
https://doi.org/10.32480/rscp.2022.27.1.61Keywords:
prognostic, infections, bronchiectasis, lung diseasesAbstract
Objective: To evaluate the morbidity and mortality of bronchiectasis, its interface with the maintenance of hospitalization rates and unsatisfactory prognostic outcomes, as well as the negative impact on Brazilian public health. Methods: The clinical and epidemiological information came from the IT department of the Brazilian Unified Health System - DataSus, from which the required data was filtered through the SUS - CID10 list of morbidities. Information was sought, in absolute numbers, regarding the hospitalization of bronchiectasis patients, such as gender, age, time and cost of hospitalization, care regime, and the number of deaths due to the disease. Results: From the variables found, it was noted that in the period from January 2008 to February 2020, around 24,087 bronchiectasis patients were hospitalized. 65% of the total number of hospitalizations due to the disease consisted of adults, with a large portion in the productive phase (between 20 and 79 years). 84% of the patients sought health units in an emergency mode and 47% used public services at the time of hospitalization. The Brazilian average length of stay in hospital was estimated at 8.1 days and the cost of the service was around R$ 28 million in the twelve years analyzed. Besides, 698 deaths due to bronchiectasis were recorded in Brazil. Conclusions: Diseases such as bronchiectasis are far from the adequate management that chronic lung diseases require. Despite the significant diagnostic evolution, the etiology and treatment of disease is still questionable, providing unsatisfactory quality of life for bronchiectasis patients.
Metrics
Downloads
References
(1) Forum of International Respiratory Societies. The Global Impact of Respiratory Disease. Forum of International Respiratory Societies; 2017.
(2) Pereira MC, et al. Brazilian consensus on non-cystic fibrosis bronchiectasis. J. Bras. Pneumol. 2019. doi: 10.1590/1806-3713/e20190122
(3) Chotirmall SH, Chalmers JD. Bronchiectasis: An emerging global epidemic. BMC Pulm. Med. 2018;8:2-4.
(4) DataSus. Departamento de Informática do Sistema Único de Saúde do Brasil; 2020.
(5) Martinez-Garcia MÁ, et al. Prognostic Value of Frequent Exacerbations in Bronchiectasis: The Relationship With Disease Severity. Arch. Bronconeumol. 2019;55:81-87.
(6) Menéndez R. et al. Factors associated with hospitalization in bronchiectasis exacerbations: A one-year follow-up study. Respir. Res. 2017;18:1-8.
(7) De La Rosa Carrillo, D. et al. The annual prognostic ability of FACED and E-FACED scores to predict mortality in patients with bronchiectasis. ERJ Open Res. 2018;4:00139-02017.
(8) Barker Alan F, Bardana Jr EJ. Bronchiectasis: Update of an Orphan Disease. Am. Rev. Respir. Dis. 1988;137:969-978.
(9) Tiddens HAW, Meerburg JJ, van der Eerden MM, Ciet P. The radiological diagnosis of bronchiectasis: What’s in a name? Eur. Respir. Rev. 2020;29:1-9.
(10) Quint JK, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: A population-based cohort study. Eur. Respir. J. 2016;7:186-193.
(11) IBGE - Instituto Brasileiro de Geografia e Estatística. Síntese de Indicadores Sociais. 2020. Available in: https://www.ibge.gov.br/estatisticas/sociais/saude/9221-sintese-de-indicadoressociais.html?=&t=o-que-e
(12) Da Silva Filho LVR F, et al. Pseudomonas aeruginosa infection in patients with cystic fibrosis: Scientific evidence regarding clinical impact, diagnosis, and treatment. J. Bras. Pneumol. 2013;39:495-512.
(13) Sahuquillo-Arce J, Méndez R, Hernández-Cabezas A, Menéndez R. Non-cystic fibrosis bronchiectasis: The long road to multidrug resistant bacteria. Community Acquir. Infect. 2016. doi: 10.4103/2225-6482.198491.
(14) McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. Am. J. Respir. Crit. Care Med. 2013;88:647-656.
(15) Redondo M, Keyt H, Dhar R, Chalmers JD. Global impact of bronchiectasis and cystic fibrosis. Breathe. 2016;12, 222–235.
(16) IBGE - Instituto Brasileiro de Geografia e Estatística. Pesquisa Nacional por Amostra de Domicílios Contínua. 2020. Available in: https://www.ibge.gov.br/estatisticas/multidominio/cultura-recreacao-e-esporte/17270-pnad-continua.html?=&t=o-que-e
(17) De La Rosa D, et al. Annual direct medical costs of bronchiectasis treatment. Chron. Respir. Dis. 2016;13:361-371.
(18) Boccolini CS. Morbimortalidade por doenças crônicas no Brasil: Situação Atual e Futura. Fundação Oswaldo Cruz; 2016.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Revista de la Sociedad Científica del Paraguay
This work is licensed under a Creative Commons Attribution 4.0 International License.
El/los autores autorizan a la Revista de la Sociedad Científica del Paraguay a publicar y difundir el articulo del cual son autores, por los medios que considere apropiado.
